Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats: RESEARCH PAPER

British Journal of Pharmacology

Volumn 158, Issue 2, 2009, Pages 541-547

  Kassan, M ^a   Montero, M J ^a   Sevilla, M A ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Endothelial dysfunction; Hypertension; Oxidative stress; Pravastatin; Ventricular hypertrophy

Indexed keywords

ACETYLCHOLINE; NITRITE; NITROPRUSSIDE SODIUM; OXYGEN; PHENYLEPHRINE; PRAVASTATIN; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EARLY DIAGNOSIS; ENDOTHELIUM CELL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MUSCLE; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR RING;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPID PEROXIDATION; MALE; NITRIC OXIDE; NITROPRUSSIDE; OXIDATIVE STRESS; PHENYLEPHRINE; PRAVASTATIN; RATS; RATS, INBRED SHR; SUPEROXIDES;

EID: 69549116708     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00339.x     Document Type: Article

References (38)

1. Adams MA, Bobik A, Korner PI (1989). Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. Hypertension 14 : 191 202.
2. Alexander SP, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
3. Alvarez de Sotomayor M, Herrera MD, Marhuenda E, Andriantsitohaina R (2000). Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Br J Pharmacol 131 : 1179 1187.
4. Chong PH, Seeger JD, Franklin C (2001). Clinically relevant differences between statins: implication for therapeutic selection. Am J Med 111 : 390 400.
5. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J (2001). Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 : 926 933.
6. Egashira K, Ni W, Inoue S, Kataoka C, Kitamoto S, Koyanagi M et al. (2000). Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent action. Hypertens Res 23 : 353 358.
7. Freeman BA, Crapo JD (1982). Biology of disease: free radicals and tissue injury. Lab Invest 47 : 412 425.
8. Guerrero EI, Ardanaz N, Sevilla MA, Arévalo MA, Montero MJ (2006). Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens 24 : 151 158.
9. Guijarro C, Blanco-Colio LM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF et al. (1999). Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int 71 (Suppl. l S88 S91.
10. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C et al. (1998). Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 : 2711 2719.
11. Iemitsu M, Miyauchi T, Maeda S, Sakai S, Kobayashi T, Fujii N et al. (2001). Physiological and pathological cardiac hypertrophy induces different molecular phenotypes in the rats. Am J Physiol Regul Integr Comp Physiol 281 : R2029 R2036.
12. Iyer RS, Singh G, Rebello S, Roy S, Bhat R, Vidyasagar D et al. (1995). Changes in the concentration of endothelin-1 during development of hypertensive rats. Pharmacology 51 : 96 104.
13. Laufs U, La Fata V, Plutzky J, Liao JK (1998). Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 : 1129 1135.
14. Laufs U, Endres M, Stagliano N, Amin-Hanjani S, Chui DS, Yang SX et al. (2000). Neuroprotection mediated by changes in the endotelial and cytosketketon. J Clin Invest 106 : 15 24.
15. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC (2005). Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289 : H220 H227.
16. McFarlane SI, Muniyappa R, Francisco R, Sowers JR (2002). Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87 : 1451 1458.
17. Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F (2001). Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 289 : 857 861.
18. Mital S, Zhang X, Zhao G, Bernstein RD, Smith CJ, Fulton DL et al. (2000). Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 279 : H2649 H2657.
19. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U et al. (2006). Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48 : 677 684.
20. Ohkawa H, Ohishi N, Yagi K (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95 : 351 358.
21. Osorio JC, Cheema FH, Martens TP, Mahmut N, Kinnear C, Gonzalez AM et al. (2008). Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor. Can J Physiol Pharmacol 86 : 633 642.
22. Reif A, Fröhlich LG, Kotsonis P, Frey A, Bömmel HM, Wink DA et al. (1999). Tetrahydrobiopterin inhibts monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem 274 : 24921 24929.
23. Rosenson RS, Tangney CC (1998). Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 : 1643 1650.
24. Sánchez M, Galisteo M, Vera R, Villar IC, Zarzuelo A, Tamargo J et al. (2006). Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 24 : 75 84.
25. Sevilla MA, Voces F, Carrón R, Guerrero EI, Ardanaz N, San Román L et al. (2004). Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. Life Sci 75 : 881 891.
26. Shinozaki K, Nishio Y, Ayajiki K, Yoshida Y, Masada M, Kashiwagi A et al. (2007). Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production. J Cardiovasc Pharmacol 49 : 122 130.
27. Takemoto M, Liao JK (2001). Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21 : 1712 1719.
28. Valdivielso JM, Crespo C, Alonso JR, Martínez-Salgado C, Eleno N, Arévalo M et al. (2001). Renal ischemia in the rat stimulates nitric oxide synthesis. Am J Physiol Regul Integr Comp Physiol 280 : R771 R779.
29. Vasa M, Fichtscherer S, Adler K, Aicher A, Martin H, Zeiher AM et al. (2001). Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 : 2885 2890.
30. Wagner AH, Ruckschloss U, Just I, Hecker M (2000). Improvement of nitric oxide-dependent vasodilataion by HMG-CoA reductase inhibitors through attenuation of endothelium superoxide anion formation. Arterioscler Thromb Vasc Biol 20 : 61 69.
31. Wassmann S, Laufs U, Bäumer AT, Müller K, Ahlbory K, Linz W et al. (2001). HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37 : 1450 1457.
32. Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT et al. (2002). Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 : 300 305.
33. Werner ER, Werner-Felmayer G, Wachter H, Mayer B (1995). Biosynthesis of nitric oxide: dependence on pteridine metabolism. Rev Physiol Biochem Pharmacol 127 : 97 135.
34. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H (2008). Pravastatin attenuates left ventricular remodelling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cadiovasc Pharmacol 51 : 62 70.
35. Yamamoto A, Hoshi K, Ichihara K (1998). Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 36 : 143 149.
36. Yang CM, Chien CS, Hsiao LD, Pan SL, Wang CC, Chiu CT et al. (2001). Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol 132 : 1531 1541.
37. Ye P, Yu D, Song L, Deng X, Zhao Y (2000). Inhibitory effect of fluvastatin on aortic intimal thickening in normocholesterolemic rabbits. Chin Med Sci J 15 : 140 144.
38. Zhou R, Xu Q, Zheng P, Yan L, Zheng J, Dai G (2008). Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 586 : 244 250.